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Background: Glucagon-like Peptide-1 (GLP-1) is an incretin hormone secreted from the gastrointestinal tract that
facilitates the glucose-dependent insulin response. Additionally, GLP-1 is thought to be involved in energy homeostasis.
Currently little is known about GLP-1’s responsiveness to an energy surplus, a fundamental cause of obesity and
diabetes. Our objective was to examine the response of serum GLP-1 to short-term (7 day) overfeeding in young men.
Methods: Seventy-two young men from the Canadian province of Newfoundland were recruited for the study.
For 7-days, the subjects consumed 70% more calories than required at baseline.
Various measurements including: anthropometrics, body composition, markers of glucose/lipid metabolism and serum
total GLP-1, were taken at a fasted state before (day 1) and after (day 8) the challenge. Paired t-test analyses were used
to assess the change in variables after the overfeeding period. Additionally, the relationship between serum GLP-1 and
the measured variables at baseline and change due to overfeeding were analyzed.
Results: Serum GLP-1 was significantly increased in all groups in response to the 7-day energy surplus, indicating
the increase was independent of adiposity status. There was no significant difference in fasting GLP-1 at baseline
between the normal weight and overweight/obese groups. At baseline, GLP-1 concentration negatively correlated
with HDL-cholesterol and positively correlated with triacylglycerols and markers of insulin resistance in the overweight/
obese group. Also GLP-1 was negatively correlated with change in percent gynoid fat in the overweight/obese
subjects. Percent change in GLP-1 was negatively associated with percent change in gynoid fat in the normal weight
group and positively associated with percent change in cholesterol in the overweight/obese group. Percentage
change of circulating triacylglycerols was positively associated with percent change in GLP-1 in both adiposity groups.
Conclusion: Our findings showed that GLP-1 serum concentration is not a significant factor in determining obesity
status. The increase of GLP-1 in all subjects regardless of obesity status, suggest GLP-1 serves as a protective role,
counteracting energy surplus.
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Hormones secreted from the gastrointestinal (GI) tract
play an important role as peripheral signals of energy
homeostasis and are thought to be involved in the deve-
lopment of obesity and diabetes [1]. Glucagon-like
peptide-1 (GLP-1) is a 30-amino acid peptide hormone
secreted from the L-cells of the distal ileum, but is also* Correspondence: gsun@mun.ca
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reproduction in any medium, provided the orpresent in the central nervous system [2]. GLP-1 is a
product of the GCG gene and is formed due to tissue-
specific post-translational modification of proglucagon.
The hormone is released into circulation in response to
food intake; the larger the meal size, the greater the
GLP-1 response [3,4]. Therefore during the fasted state,
GLP-1 is low (but still detectable) however the con-
centration rises postprandially. Active GLP-1 has a very
short half-life of ~2 minutes as it is degraded by
dipeptidyl peptidase-IV (DPP-IV) [5,6].
GLP-1 binds to its receptors present in a variety of tissues
and elicits a number of responses. For one, GLP-1 is de-
signated an incretin hormone, facilitating the glucose-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[7,8]. Also it has been shown to decrease the secretion of
glucagon in patients with type-I diabetes who have no
beta-cell function but still exhibit the lowered plasma
glucose via GLP-1 [9-11]. Other effects include, decrea-
sed appetite [12-14] and decreased gastric motility and
secretion [15,16].
Due to its many metabolic-related effects, GLP-1 has
been implicated in many chronic metabolic diseases. For
example, both its incretin effect and suppression of glu-
cagon secretion action are disrupted in type-II diabetes
[17]. It has also been shown that intravenous (IV) infu-
sion of GLP-1 acts to lower blood glucose concentration
in type-II diabetic patients [18,19]. GLP-1 is also sug-
gested to be involved in obesity as morbidly obese sub-
jects show a decreased diurnal L-cell secretion [20].
Fasting GLP-1 has been found to be lower in diabetic
and obese diabetic patients as compared to healthy con-
trols [21,22] however, not all studies have consistent
findings [23]. Additionally, the postprandial secretion of
GLP-1 is inhibited in morbidly obese subjects, which is
improved after weight loss [24,25]. It has been found
that GLP-1 infusions reduce food intake in normal
weight and obese subjects, regardless of diabetic status
[13,14,26-28].
Recognizing that obesity is a result of a chronic positive
energy imbalance, it has been shown that modification of
food intake, including overfeeding, influence various gut
hormone concentrations [29-32]. However, most human
studies on GLP-1 have been performed using a cross sec-
tional study design which may not reflect biological and
clinical relevance. The dynamic process of an energy sur-
plus will provide insights of the role of GLP-1 in the devel-
opment of obesity and diabetes [33-35]. The objectives of
the present study were therefore to investigate: a) the
GLP-1 response to short-term overfeeding in young men;
b) the difference in serum GLP-1 concentration in pre-
and post- overfeeding between various adiposity groups;
and c) the relationship of fasting GLP-1 with various
obesity-related markers.
Methods
Subjects
Seventy-two healthy men (age 19–29) from Newfoundland
and Labrador, Canada, participated in the present study.
All subjects were of at least 3rd generation Newfoundland
descent and reported a stable body weight over the last six
months. Participants had no serious endocrine, metabolic
or cardiovascular diseases, nor were taking any medica-
tions affecting lipid/cholesterol metabolism. Informed and
written consent were provided by each subject. Ethical ap-
proval was received from the Human Investigations Com-
mittee for the Faculty of Medicine, Memorial University,
St. John’s, NL, Canada.Overfeeding
Overfeeding was completed following a protocol previ-
ously described by us [31,32,36]. To assess the metabolic
and endocrine effects of a short-term energy surplus,
participants were overfed, for one week (7 days), 70%
more calories than what they would normally consume.
A 7-day overfeeding period was chosen to ensure
changes in metabolic parameters. To estimate daily
energy requirements, three 24-hour recall interviews
(2 on weekdays, 1 on weekend) and a 30-day dietary in-
ventory were administered to the subjects. A food recall
kit containing standard portion sizes was used in a
face-to-face interview, assessing the food intake of the
previous 24-hours. An average of the questionnaires was
utilized to determine daily caloric requirements. The
positive energy challenge was consistent with the typical
North American diet: 50% carbohydrates, 35% fat, and
15% protein. Throughout 7-days at time 0900, 1200, and
1700, subjects consumed meals with caloric and nutri-
tional content calculated using Food Processor SQL
(version 9.5.0.0; ESHA Research, Salem, OR). A labora-
tory member was present through the duration of all
meals. Average caloric content was 2969 kcal pre-
overfeeding and 5471 kcal during overfeeding [29].
While participating in the study, subjects were requested
to refrain from consuming additional calorie-containing
beverages, drinking alcohol, or taking drugs/medications.
Measured variables
Various physical, anthropometric and biochemical
markers were assessed after a 12-hr fasting period, be-
fore and after the 7-day overfeeding period. These are
outlined below:
Anthropometric measurements
During all anthropometric measurements subjects wore
a light standardized hospital gown. Total body weight
was assessed on a platform scale balance (Health O
Meter, IL) and height was measured using a fixed
stadiometer, to the nearest 0.1 kilogram and centimeter,
respectively. Body mass index (BMI) was calculated by
dividing the participant’s weight in kilograms by height
in meters squared (kg/m2). Both waist and hip circum-
ference were evaluated using a measuring tape to the
nearest 0.1 centimeter.
Body composition measurements
Body composition was assessed using dual-energy X-ray
absorptiometry (DXA Lunar Prodigy; GE Medical Sys-
tems, Madison, WI). The scan can differentiate between
fat, lean, and bone mass, and can therefore determine per-
cent body fat (%BF), trunk fat (%TF), android fat (%AF),
and gynoid fat (%GF) [37] (method previously described
by us [38]). Study subjects were classified as underweight,
Wadden et al. Nutrition & Metabolism 2013, 10:33 Page 3 of 9
http://www.nutritionandmetabolism.com/content/10/1/33normal weight, overweight, and obese based on percent-
age body fat recommendations by Bray (for males aged
20–39: underweight= <8.0%, normal weight= 8-20.9%,
overweight= 21–25.9%, or obese= >26.0%) [39].
Serum measurements
Venous blood was collected from subjects and after pro-
cessing, serum was stored at −80°C. Serum total choles-
terol, high-density lipoprotein cholesterol (HDL-c),
triacylglycerols (TGs), and glucose concentrations were
determined by Synchron reagents using an Lx20 clinical
chemistry analyzer (Beckman Coulter Inc., CA, USA).
The concentration of serum insulin was measured utiliz-
ing the Immulite 2500 immunoassay analyzer (Siemens,
Los Angeles, CA). The homeostasis model assessment
(HOMA) was used to estimate indices of pancreatic
β-cell function (HOMA-β: [20 × insulin (mU/L)/(glucose
(mmol/L) - 3.5)]) and insulin resistance (HOMA-IR:
[insulin (mU/L) × glucose (mmol/L)/22.5)]). The Friedwald
equation (total cholesterol – HDL-c – TG/2.2) was used
to calculate low-density lipoprotein cholesterol (LDL-c).
Serum total GLP-1 was measured in duplicate using
enzyme-linked immunosorbent assay (ELISA) kits (EMD
Millipore, St. Charles, MO). The intra-assay variation
ranged from 3.4% to 4.2%, and the inter-assay variation
(n = 4) was 5.7%.
Statistical analysis
All data are presented as mean ± S.E. unless stated
otherwise. Data not normally distributed were log-
transformed (concentrations of fasting: serum GLP-1,
triacylglycerols, insulin, HOMA-IR and HOMA-β)
where appropriate. As well, all data was analyzed using
SPSS (Version 19) and statistical tests were two-sided
with significance set at a P-value of 0.05. Because of the
small sample size (n=3) underweight subjects were com-
bined with normal weight subjects (total n=30). Add-
itionally, as there were a small number of overweight
individuals (n=14), these subjects were combined with
obese subjects (total n=42).
The differences between various markers of adiposity,
insulin resistance, lipid metabolism, and fasting GLP-1
concentration before and after the overfeeding protocol,
were assessed utilizing paired t-test analysis. Additionally a
two-factor ANOVA (repeated measures) was used to
examine the overfeeding-adiposity interaction of measured
variables. One-way ANOVA (with Bonferroni post hoc
tests) was utilized to assess the differences of variables be-
tween adiposity groups at baseline.
Spearman correlation analysis was completed to assess
the relationship between a) baseline GLP-1 serum con-
centration and aforementioned variables at baseline, b)
baseline GLP-1 serum concentration and change in the
variables; c) change in serum GLP-1 and change in thevariables; and d) baseline variables and change in serum
GLP-1. Additionally partial correlative analysis was com-
pleted controlling for potential confounding factors.
Results
Pre- and post- overfeeding descriptive statistics
Biochemical and physical measurements prior-to and after
the overfeeding challenge are presented in Table 1. Changes
in anthropometrics, body composition and measures of
glucose and lipid metabolism were previously described by
us [31,32,40]; nevertheless, it was evident that the one-
week overfeeding challenge increased body weight, adipos-
ity, serum lipids, insulin and insulin resistance. After a one
week energy surplus, circulating GLP-1 concentration rose
in the cohort. The pre- and post- overfeeding fasting con-
centrations of GLP-1 were increased from 36.84±3.16
pmol/L at baseline to 42.39±3.18 pmol/L, after overfeeding.
The average percent change in GLP-1 through the over-
feeding study was 24.10±5.85%. However based on 2-way
ANOVA repeated measure analysis, there was no signifi-
cant difference between normal weight and overweight/
obese subjects for the increase in serum GLP-1 (P=0.590).
Furthermore, there was no significant difference between
the normal weight and overweight/obese group for fasting
GLP-1 concentration at baseline (t-test: P=0.876).
Baseline correlations of GLP-1 with body composition and
markers of lipid/glucose metabolism
Table 2 characterizes the baseline relationships between
GLP-1 and the markers of adiposity, and lipid/glucose
metabolism, utilizing Spearman correlation analysis. In
the entire cohort, fasting GLP-1 concentration was nega-
tively associated with HDL-c concentration and posi-
tively associated with triacylglycerol concentration. Also
a positive relationship was evident between GLP-1 and
the ratio of total cholesterol to HDL-c. When the cohort
was grouped based on adiposity status (based on Bray
recommendations), no relationships were found between
GLP-1 concentration and the measured variables in the
normal weight group. However, in the overweight/obese
group, GLP-1 concentration remained significantly cor-
related with HDL-c, triacylglycerol concentration, and
the ratio of total cholesterol to HDL-c. Interestingly, in
the overweight/obese, a positive relationship was found
between GLP-1 concentration and insulin, HOMA-IR,
HOMA-β, and percent gynoid fat.
Due to the possible confounding effect of gynoid fat
on HDL-cholesterol, triacylglycerols, and markers of in-
sulin metabolism, partial correlations were performed
controlling for gynoid fat and all analyses were repeated
(data not shown). All of the aforementioned relation-
ships remained significant except for the relationship be-
tween GLP-1 and HOMA-β in the overweight/obese
group (r = 0.300, P = 0.053).
Table 1 Physical and biochemical characteristics of subjects at baseline and in response to 7-days of overfeeding a,b
Entire cohort (n = 72)
Day 1 Day 8 p-value Change (Δ) from baseline Average percent change from baseline (%)
Age 23.11 ± 0.37 N/A - N/A N/A
Height (cm) 179.18 ± 0.72 N/A - N/A N/A
Weight (kg)b 80.92 ± 1.81 83.13 ± 1.87 <0.001 2.21 ± 0.16 2.74 ± 0.20
BMI (kg/m2)b 25.27 ± 0.56 25.96 ± 0.58 <0.001 0.69 ± 0.05 2.74 ± 0.20
Percent body fat 22.41 ± 1.05 22.69 ± 1.00 0.051 0.28 ± 0.14 2.65 ± 0.87
Percent trunk fat 25.15 ± 1.17 25.52 ± 1.10 0.088 0.38 ± 0.21 3.25 ± 1.10
Percent android fatb 28.64 ± 1.38 29.44 ± 1.35 <0.001 0.80 ± 0.21 4.77 ± 1.37
Percent gynoid fat 27.27 ± 1.03 27.50 ± 0.99 0.221 0.23 ± 0.19 1.80 ± 0.89
Total cholesterol (mmol/L)b 4.50 ± 0.10 4.74 ± 0.10 0.007 0.23 ± 0.08 6.33 ± 1.88
HDL cholesterol (mmol/L)b 1.31 ± 0.03 1.41 ± 0.03 <0.001 0.10 ± 0.02 9.08 ± 1.88
Total cholesterol:HDLc ratiob 3.58 ± 0.10 3.47 ± 0.10 0.020 −0.10 ± 0.04 −2.11 ± 1.12
LDL cholesterol (mmol/L) 2.72 ± 0.08 2.75 ± 0.08 0.639 0.03 ± 0.06 2.88 ± 2.17
Triacylglycerols (mmol/L)b 1.08 ± 0.06 1.44 ± 0.16 0.005 0.35 ± 0.15 44.74 ± 21.54
Glucose (mmol/L) 5.10 ± 0.06 5.11 ± 0.06 0.905 0.01 ± 0.07 0.75 ± 1.31
Insulin (pmol/L)b 68.54 ± 8.27 86.84 ± 7.78 <0.001 18.29 ± 6.98 55.02 ± 9.53
HOMA-IRb 2.38 ± 0.34 2.92 ± 0.29 <0.001 0.54 ± 0.29 59.71 ± 10.77
HOMA-βb 114.57 ± 8.85 158.38 ± 12.38 <0.001 43.80 ± 9.30 50.60 ± 8.01
Serum GLP-1 (pmol/L)b 36.84 ± 3.16 42.39 ± 3.18 <0.001 5.55 ± 1.57 24.10 ± 5.85
a Values are mean ± SE. Homeostasis model assessment of insulin resistance (HOMA-IR) and of B cell function (HOMA-β); GLP-1, Glucagon-like Peptide-1; N/A,
not applicable.
b Significant difference present between pre- and post- overfeeding (paired t-test; SPSS 19.0).
Table 2 Spearman correlations of baseline variables related to baseline fasting serum GLP-1 concentration a,b
All Subjects (n = 72) Normal weight (n = 30) Overweight+Obese (n = 42)
r P r P r P
Weight (kg) 0.052 NS −0.197 NS 0.175 NS
BMI (kg/m2) −0.006 NS −0.218 NS 0.117 NS
Percent body fat 0.086 NS −0.027 NS 0.186 NS
Percent trunk fat 0.098 NS −0.059 NS 0.238 NS
Percent android fat 0.079 NS −0.075 NS 0.216 NS
Percent gynoid fat 0.141 NS −0.021 NS 0.328 0.036
Total cholesterol 0.103 NS 0.265 NS −0.037 NS
HDL cholesterol −0.357 0.002 0.141 NS −0.582 <0.001
Total cholesterol:HDLc ratio 0.383 0.001 0.182 NS 0.489 0.001
LDL cholesterol 0.077 NS 0.286 NS −0.065 NS
Triacylglycerols 0.412 <0.001 0.232 NS 0.526 <0.001
Glucose 0.157 NS 0.039 NS 0.191 NS
Insulin 0.216 NS 0.001 NS 0.394 0.010
HOMA-IR 0.207 NS 0.005 NS 0.375 0.014
HOMA-β 0.205 NS −0.074 NS 0.353 0.022
a P<0.05 (IBM SPSS Statistics 19).
b Homeostasis model assessment of insulin resistance (HOMA-IR) and of β cell function (HOMA-β); NS, non-significant. Subjects were classifed based on adiposity
recommendations by Bray as normal weight (8–20.9%), overweight (21–25.9%), or obese (>26%).
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in body composition and markers of lipid/glucose
metabolism
The correlative data between fasting baseline GLP-1
concentration and percent changes in the markers of
adiposity, and lipid and glucose metabolism were also
observed. In the entire cohort, no relationships were
present between circulating GLP-1 and changes in any
of the measurements. However when subjects were
grouped according to adiposity, a negative correlation
was revealed between GLP-1 concentration and change
in percent gynoid fat (r = −0.349, P=0.025) in the over-
weight/obese group.
Correlations between percent change in GLP-1 with percent
change in body composition and markers of lipid/glucose
metabolism
Presented in Table 3 is the correlative data between per-
cent change in GLP-1 concentration and percent change
in markers of adiposity, and markers of lipid/glucose
metabolism. In the entire cohort, change in GLP-1 was
significantly positively associated with percent change in
HDL-c, and triacylglycerols. When split based on adi-
posity status, percent change in GLP-1 was positively
correlated with percent change in triacylglycerols and
negatively correlated with percent change in gynoid fat
in the normal weight group. However, in the over-
weight/obese percent change in serum GLP-1 was sig-
nificantly positively associated with percent change in
total cholesterol and triacylglycerols.Table 3 Spearman correlations of changes in variables related
All subjects (n = 72) N
r P
Weight (kg) 0.222 NS
BMI (kg/m2) 0.223 NS
Percent body fat 0.122 NS
Percent trunk fat 0.126 NS
Percent android fat 0.206 NS
Percent gynoid fat −0.061 NS −
Total cholesterol 0.219 NS
HDL cholesterol 0.258 0.029
Total cholesterol:HDLc ratio −0.005 NS −
LDL cholesterol 0.007 NS −
Triacylglycerols 0.543 <0.001
Glucose 0.131 NS
Insulin 0.218 NS
HOMA-IR 0.212 NS
HOMA-β 0.127 NS
a P<0.05 (IBM SPSS Statistics 19).
b Homeostasis model assessment of insulin resistance (HOMA-IR) and of β cell func
recommendations by Bray as normal weight (8–20.9%), overweight (21–25.9%), or oCorrelations between percent change in GLP-1 with
baseline body composition and lipid/glucose metabolism
variables
Additionally we wanted to assess the relationship be-
tween baseline variables and percent change in GLP-1
(Table 4). In the entire cohort, baseline weight and BMI
were positively correlated with percent change in GLP-1
while baseline GLP-1 was negatively correlated with per-
cent change in GLP-1. The same relationships were
found significant in the normal weight group, when the
cohort was grouped based on adiposity. However, only
the negative relationship with baseline GLP-1 remained
significant in the overweight/obese group.
Discussion
In the current investigation we examined the response of
circulating GLP-1 to a 7-day energy surplus in 72 young
men of Newfoundland descent. The most notable finding
was that GLP-1 concentration significantly increased in
response to the overfeeding challenge. The rise in GLP-1
concentration was independent of adiposity status as the
increase of GLP-1 was present in normal weight and over-
weight/obese groups. GLP-1 has been shown to have
beneficial effects as it facilitates the glucose-dependent in-
sulin response, lowers glucagon secretion, and induces sa-
tiation [7-14]. Thus current literature suggests GLP-1
secretion would increase in response to a positive energy
challenge, counteracting the response and potentially act-
ing as a protective mechanism (cessation of appetite/regu-
lation of insulin secretion). Though this may be the case,to change in fasting serum GLP-1 concentration a,b
ormal weight (n = 30) Overweight+Obese (n = 42)
r P r P
0.354 NS 0.137 NS
0.348 NS 0.142 NS
0.168 NS 0.087 NS
0.221 NS 0.021 NS
0.286 NS 0.066 NS
0.384 0.036 0.243 NS
0.117 NS 0.334 0.030
0.321 NS 0.188 NS
0.171 NS 0.191 NS
0.085 NS 0.195 NS
0.573 0.001 0.533 <0.001
0.226 NS 0.099 NS
0.187 NS 0.271 NS
0.198 NS 0.229 NS
0.024 NS 0.174 NS
tion (HOMA-β); NS, non-significant. Subjects were classifed based on adiposity
bese (>26%).
Table 4 Spearman correlations of baseline variables related to change in fasting serum GLP-1 concentration a,b
All subjects (n = 72) Normal weight (n = 30) Overweight+Obese (n = 42)
r P r P r P
Weight (kg) 0.251 0.033 0.391 0.033 0.162 NS
BMI (kg/m2) 0.295 0.012 0.446 0.013 0.188 NS
Percent body fat 0.130 NS 0.272 NS 0.109 NS
Percent trunk fat 0.139 NS 0.307 NS 0.104 NS
Percent android fat 0.127 NS 0.278 NS 0.077 NS
Percent gynoid fat 0.068 NS 0.239 NS −0.074 NS
Total cholesterol −0.112 NS −0.255 NS −0.030 NS
HDL cholesterol −0.085 NS −0.291 NS 0.095 NS
Total cholesterol:HDLc ratio −0.012 NS 0.066 NS −0.082 NS
LDL cholesterol −0.118 NS −0.179 NS −0.115 NS
Triacylglycerols −0.151 NS −0.226 NS −0.110 NS
Glucose 0.016 NS −0.122 NS 0.124 NS
Insulin 0.135 NS 0.079 NS 0.074 NS
HOMA-IR 0.135 NS 0.059 NS 0.083 NS
HOMA-β 0.158 NS 0.248 NS 0.063 NS
GLP-1 −0.416 <0.001 −0.484 0.007 −0.396 0.009
a P<0.05 (IBM SPSS Statistics 19).
b Homeostasis model assessment of insulin resistance (HOMA-IR) and of β cell function (HOMA-β); NS, non-significant. Subjects were classifed based on adiposity
recommendations by Bray as normal weight (8–20.9%), overweight (21–25.9%), or obese (>26%).
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humans are few in number, and vary largely in terms of
overfeeding time, degree of overfeeding and macronutrient
composition. A 3-day overfeeding study in which 21 sub-
jects (15 males, 6 females) consumed 50% more calories
than baseline requirements (energy breakdown: 20% pro-
tein, 30% fat, 50% carbohydrate) showed GLP-1 was un-
changed over the duration of the study [35]. Similarly,
Brons et al. overfed 26 healthy Danish young men 50%
more calories than required (60% fat, 32.5% carbohydrates
and 7.5% protein) utilizing a 5-day high fat diet and found
no significant change in fasting circulating GLP-1 [33]. A
small study on nine lean Caucasian males also found no
significant difference in GLP-1 concentration after an
overfeeding period which ceased when 5% of body weight
was gained (average of 35 days, range of 28–43; compo-
sition: ~ 50% carbohydrates, 35% fat, 15% protein) [34].
The excess calories were provided by a liquid drink which
was used to bring total caloric intake to a value of 1.4
times the eucaloric diet. Evidently these studies differ in
regards to subject homogeneity, length and amount of en-
ergy surplus. The negative results from all three studies
could be due to the small sample size and/or shorter
period of overfeeding (first two studies). The present in-
vestigation, utilizing a fairly homogenous sample popula-
tion of young healthy men from the Newfoundland
population, observed a significant increase in serum GLP-
1 after a 7-day overfeeding challenge consistent with a typ-
ical North American diet (50% carbohydrates, 35% fat,and 15% protein). We suggest that the increase in GLP-1
was a homeostatic protective mechanism to offset the
metabolic disturbance caused by the energy surplus.
Previous studies have suggested that obese individuals
have a lower GLP-1 secretion as compared to lean indivi-
duals [20,24,25,41]. In our cohort, we found no significant
difference in fasting GLP-1 concentration between over-
weight/obese and normal weight subjects. In the entire co-
hort we found no significant relationship between baseline
GLP-1 concentration and markers of adiposity including
BMI and percent body fat. However, in the overweight/
obese group we found baseline GLP-1 correlated with per-
cent gynoid fat. In general, women are more likely to have
greater gynoid fat distribution, and having this distribution
is thought to oppose cardiovascular diseases through more
efficient fat storage/lipoprotein lipase functionality [42,43].
Additionally in the overweight/obese group baseline
GLP-1 concentrations correlated with a negative change
in percent gynoid fat. In other words, individuals with
higher GLP-1 concentration had a smaller change in per-
cent gynoid fat after the positive energy challenge; there-
fore the finding suggests higher baseline GLP-1 predicted
a reduced gain in percent gynoid fat. Moreover, change in
GLP-1 was negatively associated with a change in gynoid
fat within the normal weight group, again proposing a
protective effect of GLP-1. Nevertheless, with lack of
large-scale studies assessing GLP-1 and overfeeding we
cannot fully elucidate the predictor ability of baseline/
change in GLP-1 on change in metabolic variables.
Wadden et al. Nutrition & Metabolism 2013, 10:33 Page 7 of 9
http://www.nutritionandmetabolism.com/content/10/1/33In this study we also observed the relationships between
GLP-1 and markers of lipid metabolism and insulin resist-
ance. At baseline when controlling for percent gynoid fat,
GLP-1 was positively correlated with triacylglycerols and
markers of insulin resistance and negatively correlated with
HDL cholesterol, in the overweight/obese group. Thus
taken together, overweight/obese subjects with higher cir-
culating baseline GLP-1 have a less favourable lipid profile
(higher triacylglycerols, lower HDL cholesterol) and higher
insulin resistance (increased HOMA-IR, HOMA-β, and in-
sulin). This being said, studies have shown administration
of GLP-1 receptor agonists to be associated with a benefi-
cial change in lipid profile and insulin resistance [44-47].
Still however, a study by de Luis et al. [48] found that after
biliopancreatic diversion surgery in morbidly obese pa-
tients, basal GLP-1 was negatively associated with HDL-c,
consistent with our findings. Additionally it has been found
that higher circulating GLP-1 in subjects with metabolic
syndrome, are at greater risk for cardiovascular disease
[49]. When we observed the relationship between percent
change in GLP-1 and percent change in triacylglycerols, a
positive association was found in both the normal weight
and overweight/obese cohorts (also change in cholesterol
was positively correlated with change in GLP-1 in the
overweight/obese cohort). We theorize that the increased
GLP-1 is trying to compensate for the increase in both
triacylglycerols and total cholesterol. However, because our
study is a forced overfeeding intervention (subjects ate 70%
more calories than required a day) the metabolic disturb-
ance caused by overfeeding potentially overwhelmed GLP-
1’s potential effect. Nevertheless more studies are necessary
to elucidate the role of GLP-1 in lipid/glucose metabolism.
A limitation of this investigation is that only young
men (age 19–29) of Newfoundland descent were studied
for one week; therefore similar studies are needed in fe-
males, and subjects of different age ranges and ethnic
groups. Further large-scale overfeeding studies assessing
such cohorts are warranted to fully elucidate the role of
GLP-1 during a positive energy surplus. Additionally,
only total human GLP-1 was measured rather than the
suggested active form, GLP-1 (7–36 amide). Active GLP-1
has a very short half-life and is found in low concentra-
tions, before it is degraded by DPP-IV, while total GLP-1
gives an indication of the secretion from intestinal L-cells.
However, total GLP-1 has been shown to positively correl-
ate with active GLP-1 (7-36amide) concentration [50].
Furthermore, although macronutrient composition was
relatively constant, we did not account for the compos-
ition of fat (polyunsaturated, saturated, etc.) or carbohy-
drate (complex vs. simple sugars).
Conclusion
Overall, our study investigated the response of fasting
GLP-1 concentration to a 7-day overfeeding protocol ina total of 72 young men from the Canadian province of
Newfoundland. In response to the short term energy sur-
plus, circulating GLP-1 significantly increased in the entire
cohort, regardless of adiposity. We suggest that the in-
creased GLP-1 may act as a protective mechanism to
counteract the positive energy challenge. Additionally at
baseline, there was no significant difference in fasting
GLP-1 concentration between the lean and overweight/
obese groups. However at baseline, GLP-1 was positively
correlated with triacylglycerols and markers of insulin
resistance, and negatively associated with HDL-c in
overweight/obese individuals. Also in this group, base-
line GLP-1 was negatively associated with percent
change in percent gynoid fat. Percent change in GLP-1
was associated with percent change in specific variables
of lipid metabolism (triacylglycerols, total cholesterol)
in the overweight/obese group. Although the positive
relationship between percent change in triacylglycerols
and percent change in GLP-1 was present in the normal
weight group, a negative relationship existed between
percent change in gynoid fat and percent change in
GLP-1. Our results suggest that GLP-1 can potentially
serve as a protective factor in obesity and it is involved
in lipid/glucose metabolism and fat distribution.
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